Key result
Anticoagulant treatment for neonatal thrombosis was associated with complete clot resolution in 68% of treated neonates versus 86% of expectantly managed neonates.
Why the study?
Does anticoagulant treatment improve clot resolution compared to expectant management in neonates with thrombotic events?
Cohort (n=32)
No
Does anticoagulant treatment improve clot resolution compared to expectant management in neonates with thrombotic events?
Complete or partial clot resolution in neonatal thrombosis occurred in both treated and expectantly managed groups, highlighting the need for randomized trials to determine optimal management.
Should not yet change neonatal thrombosis management; randomized trials needed to clarify anticoagulation benefit.
Objective. To determine the incidence, management, complications, and outcome in neonates with thrombotic events. Study Design. We performed a retrospective study of all neonates with thrombotic events admitted to our neonatal intensive care unit from January 2004 to July 2010. Results. Thrombotic events were identified in 32 of 4734 neonates (0.7%). Seven neonates were managed expectantly and 25 neonates received anticoagulant treatment. Complete resolution of the clot within 3 months of age was found in 68% (17/25) of the treated and in 86% (6/7) of the nontreated neonates. Major complications due to anticoagulant therapy occurred in 3/25 cases (12%) and included severe hemorrhage (n = 2) and abscess at the injection site (n = 1). Conclusion. Complete or partial clot resolution in neonatal thrombosis occurred in both the treated group and nontreated group. Randomized controlled trials are warranted to determine the optimal management in neonatal thrombosis.
No takes yet. Share an insight, caveat, or question.
Elteren et al. (2011) conducted a cohort in Neonatal thrombosis (n=32). Anticoagulant treatment vs. Expectant management was evaluated on Complete resolution of the clot within 3 months of age. Anticoagulant treatment for neonatal thrombosis was associated with complete clot resolution in 68% of treated neonates versus 86% of expectantly managed neonates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: